| 摘要 |
<p>Medical intervention cost reimbursement on a clinical outcome-dependent basis may be implemented through a periodic cost reimbursement instrument, such as an annuity, associated with the delivery of acute or other discrete event medical intervention, such as gene therapy, cell therapy, or medical nanotechnology.</p> |
